Cleveland Clinic to Assess Heart Risk Associated with Celebrex

CLEVELAND - Nearly 20,000 patients around the globe will participate in a study designed to determine whether Celebrex poses a risk of cardiovascular injury, according to a statement issued by the clinic that will conduct the study.

According to a report issued Dec. 13 by the Cleveland Clinic, enrollment will begin this year for the PRECISION trial, a study designed to gauge the relative safety of the three most commonly used pain relievers in the treatment of arthritis.

Cleveland Clinic Medical Director Steven E. Nissen, M.D., will act as lead investigator for the trial, which will be funded by Celebrex …